Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Current Leases (2021 - 2025)

Nurix Therapeutics (NRIX) has disclosed Current Leases for 5 consecutive years, with $2.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Leases fell 64.76% to $2.8 million in Q4 2025 year-over-year; TTM through Nov 2025 was $2.8 million, a 64.76% decrease, with the full-year FY2025 number at $2.8 million, down 64.76% from a year prior.
  • Current Leases was $2.8 million for Q4 2025 at Nurix Therapeutics, down from $3.8 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $8.0 million in Q4 2024 to a low of $2.8 million in Q4 2025.
  • A 5-year average of $5.8 million and a median of $5.5 million in 2022 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: skyrocketed 43.75% in 2022, then tumbled 64.76% in 2025.
  • Nurix Therapeutics' Current Leases stood at $3.8 million in 2021, then skyrocketed by 43.75% to $5.5 million in 2022, then soared by 35.42% to $7.5 million in 2023, then rose by 7.01% to $8.0 million in 2024, then crashed by 64.76% to $2.8 million in 2025.
  • Per Business Quant, the three most recent readings for NRIX's Current Leases are $2.8 million (Q4 2025), $3.8 million (Q3 2025), and $5.2 million (Q2 2025).